LOGIN  |  REGISTER
Cue Biopharma

Bio-Rad Laboratories (NYSE: BIO) Stock Quote

Last Trade: US$304.28 8.75 2.96
Volume: 296,635
5-Day Change: 12.66%
YTD Change: -5.77%
Market Cap: US$7.140B

Latest News From Bio-Rad Laboratories

HERCULES, Calif. / May 30, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Anette Engelhardt will join the company as its new Executive Vice President and President of the Clinical Diagnostics Group, effective June 10, 2024. Ms. Engelhardt joins Bio-Rad from Cepheid, a wholly owned subsidiary of Danaher... Read More
HERCULES, Calif. / May 23, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Executive Officer Norman Schwartz and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the Jefferies Global Healthcare Conference on Thursday, June 6, 2024, at 10:30 AM Eastern... Read More
HERCULES, Calif. / May 07, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024. First-quarter 2024 total net sales were $610.8 million, a decrease of 9.8 percent compared to $676.8 million reported for the first quarter of 2023. On a currency-neutral... Read More
HERCULES, Calif. / May 01, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that its Chief Operating Officer Andy Last and Chief Financial Officer Roop K. Lakkaraju will participate in a fireside chat event during the RBC Capital Markets Global Healthcare Conference on Tuesday, May 14, 2024, at 2:05 PM Eastern... Read More
HERCULES, Calif. / Apr 26, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced the promotion of James J. Barry, currently Senior Vice President of Global Manufacturing, to the position of Executive Vice President and President of the Life Science Group, effective May 1, 2024. He succeeds Dr. Simon May, who has... Read More
HERCULES, Calif. / Apr 18, 2024 / Business Wire / Bio-Rad Laboratories, Inc. ( NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for the first quarter of 2024 on Tuesday, May 7, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To... Read More
HERCULES, Calif. / Apr 10, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Dr. Andrew Last, Executive Vice President and Chief Operating Officer, is planning to retire by early September of 2024. Dr. Last will remain part of Bio-Rad’s executive leadership team to ensure a smooth transition while the... Read More
HERCULES, Calif. / Mar 20, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that Roop K. Lakkaraju will join the company as its new Executive Vice President and Chief Financial Officer, effective April 15, 2024. Mr. Lakkaraju joins Bio-Rad from Benchmark Electronics, a multi-national leader in electronics... Read More
HERCULES, Calif. / Feb 22, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company’s management will participate in a fireside chat event during Citi's 2024 Unplugged Medtech and Life Sciences Access Day on Thursday, February 29, 2024, at 2:30 PM Eastern Time (11:30 AM Pacific Time). A live webcast... Read More
HERCULES, Calif. / Feb 15, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the fourth quarter and full year ended December 31, 2023. Fourth-quarter 2023 total net sales were $681.2 million, a decrease of 6.7 percent compared to $730.3 million reported for the fourth quarter of 2022. On a... Read More
HERCULES, Calif. / Jan 24, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the fourth quarter and full year 2023 on Thursday, February 15, 2024, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time)... Read More
HERCULES, Calif. / Jan 02, 2024 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced that Norman Schwartz, President and CEO, and Andrew Last, Executive Vice President and COO, will host one-on-one meetings with investors during the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, January 8 - 11, 2024.... Read More
HERCULES, Calif. / Oct 26, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, today announced financial results for the third quarter ended September 30, 2023. Third-quarter 2023 total net sales were $632.1 million, a decrease of 7.1 percent compared to $680.8 million reported for the third quarter of 2022. On a currency-neutral... Read More
HERCULES, Calif. / Oct 05, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostics products, will report its financial results for the third quarter of 2023 on Thursday, October 26, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To... Read More
HERCULES, Calif. / Aug 28, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Wells Fargo’s 2023 Healthcare Conference on Thursday, September 7 at 11:00 AM Eastern Time (8:00 AM Pacific Time). A live webcast and subsequent replay of the... Read More
HERCULES, Calif. / Aug 03, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the second quarter ended June 30, 2023. Second-quarter 2023 net sales were $681.1 million, a decrease of 1.4 percent compared to $691.1 million reported for the second quarter of 2022. On a currency-neutral basis,... Read More
HERCULES, Calif. / Jul 20, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that its board of directors approved a new share repurchase program that grants the Company authority to repurchase up to $500 million of outstanding shares of its common stock. “The new share buyback authorization is consistent with our... Read More
HERCULES, Calif. / Jul 10, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the second quarter of 2023 on Thursday, August 3, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To... Read More
HERCULES, Calif. / Jul 10, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today released its corporate sustainability report for fiscal year ended December 31, 2022. The report has been prepared with reference to the Global Reporting Initiative (GRI) 2021 Standards and in alignment with the Sustainability Accounting Standards... Read More
HERCULES, Calif. / Jun 01, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the Jefferies Healthcare Conference on Thursday, June 8, 2023, at 3 PM Eastern Time. The presentation will be followed by a Q&A session with participation from... Read More
HERCULES, Calif. / May 08, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during the 2023 RBC Capital Markets Global Healthcare Conference on Wednesday, May 17, 2023, at 3:35 PM Eastern Time (12:35 PM Pacific Time). A live webcast and... Read More
HERCULES, Calif. / May 04, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the first quarter ended March 31, 2023. First-quarter 2023 net sales were $676.8 million, a decrease of 3.3 percent compared to $700.1 million reported for the first quarter of 2022. On a currency-neutral basis,... Read More
HERCULES, Calif. / Apr 12, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the first quarter of 2023 on Thursday, May 4, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To... Read More
HERCULES, Calif. / Feb 17, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that the company’s management will participate in a fireside chat event during Citi’s 2023 Healthcare Services, MedTech, Tools & HCIT Conference on Thursday, March 2, 2023, at 11:45 AM Eastern Time (8:45 AM Pacific Time). A link to a live... Read More
HERCULES, Calif. / Feb 16, 2023 / Business Wire / Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced financial results for the fourth quarter and full year ended December 31, 2022. Fourth-quarter 2022 net sales were $730.3 million, a decrease of 0.3 percent compared to $732.8 million reported for the fourth quarter of 2021. COVID-related... Read More
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, will report its financial results for the fourth quarter and full year 2022 on Thursday, February 16, 2023, following the close of the market. Management will discuss these results in a conference call scheduled for 2 PM Pacific Time (5 PM Eastern Time) that day. To participate, dial 844-200-6205 within... Read More
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader in life science research and clinical diagnostic products, today announced that Norman Schwartz, President and CEO, will present a company overview at the 41 st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 4:30 p.m. Pacific Time. The presentation will be followed by a Q&A session with participation from Bio-Rad’s Executive Vice... Read More
Compass Therapeutics

COPYRIGHT ©2023 HEALTH STOCKS HUB